Interpace Biosciences, Inc., a leading player in the biotechnology sector, is headquartered in the United States, with significant operations across various regions. Founded in 2008, the company has established itself as a pioneer in molecular diagnostics and personalised medicine, focusing on innovative solutions for cancer detection and management.
Interpace offers a range of unique products and services, including its proprietary tests that aid in the diagnosis and treatment of thyroid and other cancers. These offerings are distinguished by their ability to provide actionable insights, enhancing patient care and clinical decision-making. With a strong market position, Interpace has achieved notable milestones, including partnerships with healthcare providers and advancements in genomic testing technologies, solidifying its reputation as a trusted resource in the evolving landscape of precision medicine.
-15 vs industry average
Interpace Biosciences, Inc.’s score of 18 is lower than 30% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Interpace Biosciences, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Business Services has below-average carbon intensity
Industry performance
The Business Services industry has increased its overall emissions by 24% since 2019
Reported emissions
No reported emissions data is available for Interpace Biosciences, Inc. yet.
Interpace Biosciences, Inc.'s reported carbon emissions
Interpace Biosciences, Inc., headquartered in the US, currently does not have available carbon emissions data for the most recent year. As a result, there are no specific figures regarding their total emissions, which would typically encompass Scope 1, Scope 2, and Scope 3 emissions.
Furthermore, the company has not outlined any specific reduction targets or commitments related to climate initiatives. There are no documented climate pledges or initiatives such as the Science Based Targets initiative (SBTi) or others that would indicate a structured approach to reducing carbon emissions.
In the absence of emissions data and reduction commitments, it is unclear how Interpace Biosciences, Inc. is addressing climate change within its operations. The lack of transparency in emissions reporting may reflect broader industry challenges in establishing comprehensive climate strategies.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Interpace Biosciences, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Interpace Biosciences, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Interpace Biosciences, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project